Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-AAZTA-093 PET/CT: First-in-human Study
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.
Official title: 68Ga-AAZTA-093 PET/CT: First-in-human Study in Patients With Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-04-01
Completion Date
2024-10-01
Last Updated
2024-05-31
Healthy Volunteers
No
Conditions
Interventions
68Ga-AAZTA-093
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
68Ga-PSMA-11//68Ga-PSMA-617
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China